Clinical trial

CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation

NCT06465537

Study summary

ClinicalTrials.gov

CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation

Design: INTERVENTIONAL · Status: SUSPENDED · Phase: NA

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

GENETIC · Unmapped registry intervention BD113vVLP Find medicine records · Find other trials using this name

StatusSUSPENDED

Study typeINTERVENTIONAL

Start date2024-06-10

PhaseNA

Conditions

Primary Open Angle Glaucomaunresolved

Interventions

BD113vVLPGENETIC

Sponsors & collaborators

Shanghai BDgene Co., Ltd.lead sponsor

Beijing Tongren Hospitalcollaborator

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06465537 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.